Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Abstract

BACKGROUND:

HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina, anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts and recurrent respiratory papillomatis. In the context of the arrival of a nonavalent HPV vaccine (6/11/16/18/31/33/45/52/58), this analysis aims to estimate the public health impact and the incremental cost-effectiveness of a universal (girls and boys) vaccination program with a nonavalent HPV vaccine as compared to the current universal vaccination program with a quadrivalent HPV vaccine (6/11/16/18), in Austria.

METHOD:

A dynamic transmission model including a wide range of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and genital warts was calibrated to Austrian epidemiological data. The clinical impact due to the 5 new types was included for cervical and anal diseases outcomes only. In the base case, a two-dose schedule, lifelong vaccine type-specific protection and a vaccination coverage rate of 60% and 40% for girls and boys respectively for the 9-year old cohorts were assumed. A cost-effectiveness threshold of €30,000/QALY-gained was considered.

RESULTS:

Universal vaccination with the nonavalent vaccine was shown to reduce the incidence of HPV16/18/31/33/45/52/58 -related cervical cancer by 92%, the related CIN2/3 cases by 96% and anal cancer by 83% and 76% respectively in females and males after 100 years, relative to 75%, 76%, 80% and 74% with the quadrivalent vaccine, respectively. Furthermore, the nonavalent vaccine was projected to prevent an additional 14,893 cases of CIN2/3 and 2544 cases of cervical cancer, over 100 years. Depending on the vaccine price, the strategy was shown to be from cost-saving to cost-effective.

CONCLUSION:

The present evaluation showed that vaccinating 60% of girls and 40% of boys aged 9 in Austria with a 9-valent vaccine will substantially reduce the incidence of cervical cancer, CIN and anal cancer compared to the existing strategy. The vaccination strategies performed with the 9-valent vaccine in the current study were all found to be cost-effective compared to the current quadrivalent vaccination strategy by considering a cost-effectiveness threshold of 30,000€/QALY gained.

• Authors: L Boiron, E Joura, N Largeron, B Prager, M Uhart
• Journal: BMC infectious diseases (BMC Infect Dis) Vol. 16 Pg. 153 (Apr 16 2016) ISSN: 1471-2334 [Electronic] England
• PMID: 27084683 (Publication Type: Journal Article)

Chemical References

• Papillomavirus Vaccines

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anus Neoplasms (economics, prevention & control)
• Austria (epidemiology)
• Cost-Benefit Analysis
• Female
• Human papillomavirus 16 (immunology)
• Human papillomavirus 18 (immunology)
• Humans
• Incidence
• Male
• Middle Aged
• Models, Theoretical
• Papillomavirus Infections (economics, epidemiology, prevention & control)
• Papillomavirus Vaccines (immunology)
• Penile Neoplasms (economics, prevention & control)
• Public Health
• Quality-Adjusted Life Years
• Uterine Cervical Neoplasms (diagnosis, epidemiology)
• Vaccination
• Young Adult